期刊
TRENDS IN CARDIOVASCULAR MEDICINE
卷 29, 期 1, 页码 29-39出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tcm.2018.06.001
关键词
Cardio-oncology; Cardiotoxicity; Tyrosine kinase inhibitors; Proteasome inhibitors
There have been significant advances in the field of oncology leading to improved survival as a result of novel targeted and immunotherapies. Despite these improved outcomes, there is increased recognition of cardiotoxicities associated with these therapies that can lead to significant morbidity and mortality. As such, the field of cardio-oncology has seen significant growth over the last several years. In this review, we discuss recent advances in the field of cardio-oncology and provide a detailed discussion of the cardiovascular complications associated with novel cancer therapeutics including tyrosine kinase inhibitors, proteasome inhibitors, histone deacetylase inhibitors, CDK4/6 inhibitors and immunotherapies. (C) 2018 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据